208 related articles for article (PubMed ID: 25144718)
41. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens.
Rodríguez-Hernández CJ; Mateo-Lozano S; García M; Casalà C; Briansó F; Castrejón N; Rodríguez E; Suñol M; Carcaboso AM; Lavarino C; Mora J; de Torres C
Oncotarget; 2016 Mar; 7(13):16112-29. PubMed ID: 26893368
[TBL] [Abstract][Full Text] [Related]
42. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
43. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
44. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
[TBL] [Abstract][Full Text] [Related]
45. A tumor suppressor function for caspase-2.
Ho LH; Taylor R; Dorstyn L; Cakouros D; Bouillet P; Kumar S
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5336-41. PubMed ID: 19279217
[TBL] [Abstract][Full Text] [Related]
46. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
47. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
48. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
[TBL] [Abstract][Full Text] [Related]
49. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
Alam G; Cui H; Shi H; Yang L; Ding J; Mao L; Maltese WA; Ding HF
Am J Pathol; 2009 Aug; 175(2):856-66. PubMed ID: 19608868
[TBL] [Abstract][Full Text] [Related]
50. Targeted expression of MYCN causes neuroblastoma in transgenic mice.
Weiss WA; Aldape K; Mohapatra G; Feuerstein BG; Bishop JM
EMBO J; 1997 Jun; 16(11):2985-95. PubMed ID: 9214616
[TBL] [Abstract][Full Text] [Related]
51. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Chanthery YH; Gustafson WC; Itsara M; Persson A; Hackett CS; Grimmer M; Charron E; Yakovenko S; Kim G; Matthay KK; Weiss WA
Sci Transl Med; 2012 Jan; 4(115):115ra3. PubMed ID: 22218692
[TBL] [Abstract][Full Text] [Related]
52. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
53. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
54. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.
Zirath H; Frenzel A; Oliynyk G; Segerström L; Westermark UK; Larsson K; Munksgaard Persson M; Hultenby K; Lehtiö J; Einvik C; Påhlman S; Kogner P; Jakobsson PJ; Henriksson MA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10258-63. PubMed ID: 23733953
[TBL] [Abstract][Full Text] [Related]
55. Impaired antioxidant defence and accumulation of oxidative stress in caspase-2-deficient mice.
Shalini S; Dorstyn L; Wilson C; Puccini J; Ho L; Kumar S
Cell Death Differ; 2012 Aug; 19(8):1370-80. PubMed ID: 22343713
[TBL] [Abstract][Full Text] [Related]
56. MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.
Planells-Ferrer L; Urresti J; Soriano A; Reix S; Murphy DM; Ferreres JC; Borràs F; Gallego S; Stallings RL; Moubarak RS; Segura MF; Comella JX
Cell Death Dis; 2014 Sep; 5(9):e1401. PubMed ID: 25188511
[TBL] [Abstract][Full Text] [Related]
57. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death.
Teitz T; Lahti JM; Kidd VJ
J Mol Med (Berl); 2001 Aug; 79(8):428-36. PubMed ID: 11511973
[TBL] [Abstract][Full Text] [Related]
58. Neuroblastoma models for insights into tumorigenesis and new therapies.
Kiyonari S; Kadomatsu K
Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
[TBL] [Abstract][Full Text] [Related]
59. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
60. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.
Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M
Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]